BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

OBJECTIVE: Obesity and its associated comorbidities represent a global health challenge with a need for well-tolerated, effective, and mechanistically diverse pharmaceutical interventions. Oxyntomodulin is a gut peptide that activates the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Tina, Thomas, Leo, Baader-Pagler, Tamara, Haebel, Peter, Simon, Eric, Reindl, Wolfgang, Bajrami, Besnik, Rist, Wolfgang, Uphues, Ingo, Drucker, Daniel J., Klein, Holger, Santhanam, Rakesh, Hamprecht, Dieter, Neubauer, Heike, Augustin, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679702/
https://www.ncbi.nlm.nih.gov/pubmed/36356832
http://dx.doi.org/10.1016/j.molmet.2022.101633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679702/
https://www.ncbi.nlm.nih.gov/pubmed/36356832
http://dx.doi.org/10.1016/j.molmet.2022.101633

Ejemplares similares